Literature DB >> 24606448

Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.

Firoz Ahmad1, Rupali Mohota, Savita Sanap, Swarna Mandava, Bibhu Ranjan Das.   

Abstract

Mutations in the DNMT3A and IDH genes represent the most common genetic alteration after FLT3/NPM1 in acute myeloid leukemia (AML). We here analyzed the frequency and distribution pattern of DNMT3A and IDH mutations and their associations with other molecular markers in normal karyotype AML patients. Forty- five patients were screened for mutations in DNMT3A (R882), IDH1 (R132) and IDH2 (R140 and R172) genes by direct sequencing. Of the 45 patients screened, DNMT3A and IDH mutations were observed in 6 (13.3%) and 7 (15.4%), respectively. Patients with isolated DNMT3A mutations were seen in 4 cases (9%), isolated IDH mutations in 5 (11.1%), while interestingly, two cases showed both DNMT3A and IDH mutations (4.3%). Nucleotide sequencing of DNMT3A revealed missense mutations (R882H and R882C), while that of IDH revealed R172K, R140Q, R132H and R132S. Both DNMT3A and IDH mutations were observed only in adults, with a higher frequency in males. DNMT3A and IDH mutations were significantly associated with NPM1, while trends towards higher coexistence with FLT3 mutations were observed. This is the first study to evaluate DNMT3A/ IDH mutations in Indian patients. Significant associations among the various molecular markers was observed, that highlights cooperation between them and possible roles in improved risk stratification.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24606448     DOI: 10.7314/apjcp.2014.15.3.1247

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  13 in total

1.  A Case Report of Concurrent IDH1 and NPM1 Mutations in a Novel t(X;2)(q28;p22) Translocation in Acute Myeloid Leukaemia without Maturation (AML-M1).

Authors:  Sureshkumar Raveendran; Santhi Sarojam; Sangeetha Vijay; Shruti Prem; Hariharan Sreedharan
Journal:  Malays J Med Sci       Date:  2015-09

Review 2.  Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia.

Authors:  Bian-Hong Wang; Yong-Hui Li; Li Yu
Journal:  Chin Med J (Engl)       Date:  2015-09-05       Impact factor: 2.628

3.  FLT3-ITD, NPM1, and DNMT3A Gene Mutations and Risk Factors in Normal Karyotype Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients in Upper Northern Thailand

Authors:  Piyanan Mevatee; Adisak Tantiworawit; Patrinee Traisathit; Chaniporn Puaninta; Umnat Mevatee; Sirinda Angsuchawan; Kanokkan Bumroongkit
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

4.  Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups

Authors:  Samreen Zehra; Rahela Najam; Tasneem Farzana; Tahir Shamsi
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

5.  Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia

Authors:  Tanasan Sirirat; Suporn Chuncharunee; Pimjai Nipaluk; Teerapong Siriboonpiputtana; Takol Chareonsirisuthigul; Nittaya Limsuwannachot; Budsaba Rerkamnuaychoke
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

6.  Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.

Authors:  Li Ye; Yanling Ren; Xinping Zhou; Chen Mei; Liya Ma; Xingnong Ye; Juying Wei; Weilai Xu; Haitao Meng; Wenbin Qian; Wenyuan Mai; Yinjun Lou; Gaixiang Xu; Jiejing Qian; Yejiang Lou; Yingwan Luo; Lili Xie; Peipei Lin; Chao Hu; Jie Jin; Hongyan Tong
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-20       Impact factor: 4.553

Review 7.  Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.

Authors:  Hanumantha Rao Madala; Surendra R Punganuru; Viswanath Arutla; Subhasis Misra; T J Thomas; Kalkunte S Srivenugopal
Journal:  Cancers (Basel)       Date:  2018-02-11       Impact factor: 6.639

8.  Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.

Authors:  Peipei Lin; Yingwan Luo; Shuanghong Zhu; Dominic Maggio; Haiyang Yang; Chao Hu; Jinghan Wang; Hua Zhang; Yanling Ren; Xinping Zhou; Chen Mei; Liya Ma; Weilai Xu; Li Ye; Zhengping Zhuang; Jie Jin; Hongyan Tong
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-16       Impact factor: 4.322

9.  Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.

Authors:  Bianhong Wang; Yangyang Liu; Guangyuan Hou; Lili Wang; Na Lv; Yuanyuan Xu; Yihan Xu; Xiuli Wang; Zhaoling Xuan; Yu Jing; Honghua Li; Xiangshu Jin; Ailing Deng; Li Wang; Xiaoning Gao; Liping Dou; Junbin Liang; Chongjian Chen; Yonghui Li; Li Yu
Journal:  Oncotarget       Date:  2016-05-31

10.  IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics.

Authors:  Yasser H ElNahass; Ragia H Badawy; Fatma A ElRefaey; Hend A Nooh; Dalia Ibrahiem; Heba A Nader; Hossam K Mahmoud; Wafaa H ElMetnawy
Journal:  Asian Pac J Cancer Prev       Date:  2020-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.